FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel to treat metastatic non–small cell lung cancer that has not responded to platinum-based treatment.
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 i
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung cancer cells. This innovative technology is based on the use with low intensity and with continuity of electric fields that operate with different frequencies and it has been presented in some clinical trials.
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first tre | Novocure described its Tumor Treating Fields therapy as the first of its kind for the aggressive cancer,
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of
FDA approves Novocure’s Optune Lua
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
Novocure shares surge on cancer treatment approval, and other movers
Novocure shares are surging 35% after the company said that the [Food and Drug Administration had approved Optune Lua](
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
Novocure stock rocketed late Tuesday after the FDA signed off on its treatment for patients with metastatic lung cancer.
MassDevice15h
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...
clinicaltrialsarena on MSN17h
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
NovoCure’s Optune Lua, a wearable indicated for patients with metastatic non-small cell lung cancer has received approval ...
Targeted Oncology1d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...